A modern view of LGL leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Large granular lymphocytic leukemia (LGLL) is a rare, chronic lymphoproliferative disorder involving cytotoxic T or NK cells.
• It predominantly affects older individuals and is often linked to autoimmune conditions like rheumatoid arthritis.
• Disease initiation is thought to involve auto-/alloantigen triggers and proinflammatory cytokines.

Purpose of the Study:

• To review recent advances in understanding the molecular pathogenesis of T- and NK-LGLL.
• To highlight key genetic mutations and immune microenvironment interactions.
• To discuss current and emerging therapeutic strategies for LGLL.

Main Methods:

• Review of recent scientific literature on LGLL.
• Analysis of molecular mechanisms including genetic mutations (e.g., JAK-STAT, TET2, KMT2D) and cytokine signaling (e.g., IL-15, MIP-1, RANTES).
• Evaluation of treatment outcomes with conventional immunosuppressants and novel targeted therapies.

Main Results:

• Recurrent STAT3 gain-of-function mutations and epigenetic alterations (TET2, KMT2D) are implicated in LGLL pathogenesis.
• The JAK-STAT pathway is crucial for LGL cell survival, proliferation, and cytotoxicity.
• Cross-talk with the immune microenvironment, such as CCL22, also plays a role.
• While often indolent, many patients eventually require treatment, with targeted therapies showing promise.

Conclusions:

• LGLL pathogenesis involves complex genetic and immune dysregulation.
• Targeted therapies, including JAK-STAT inhibitors and hypomethylating agents, represent promising new avenues for managing this incurable disease.
• Further research into molecular drivers and immune interactions is essential for developing more effective treatments.